GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
Synonyms: compound 30h [PMID: 39561495] | EDT-001
Compound class:
Synthetic organic
Comment: EDT001 (Enterprise Therapeutics) is a long-acting epithelial sodium channel (ENaC) inhibitor [1-2]. It is proposed as a novel therapeutic modality for cystic fibrosis (CF), that acts to inhibit ENaC's absorptive function as a mechanism to aid hydration in CF airways. It is designed for administration via inhalation, to selectively target ENaC in the lungs and avoid disruption of ENaC function in the kidney.
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
Bioactivity Comments |
Inhibits ENaC-mediated spontaneous current in primary human bronchial epithelial-like cultures in vitro (IC50 57 nM) [1]. Active in a sheep model of mucociliary clearance, determined as improved clearance of 99mTc-labeled particles applied directly to the airways. |
Selectivity at ion channels | ||||||||||||||||||||||||||||||||||
Key to terms and symbols | Click column headers to sort | |||||||||||||||||||||||||||||||||
|